Increasing microbial resistance is creating a demand for new drugs, which is currently not matched by privately-funded research and development, making it all the more important to obtain protection with smart, cost effective IP strategies for novel inventions addressing the innovation void.  

The repurposing of drugs can also be protected by patents, which requires experience and expertise in second-medical use claims to provide the best possible support. 

Universities and research institutions, start-up companies and SMEs all benefit from the wide-ranging, commercially relevant experience of HGF’s anti-infectives IP team, who possess deep knowledge and understanding of the shifting patent laws that affect innovators in areas relating to anti-infective agents.  

HGF’s specialist attorneys combine extensive legal, scientific and transactional expertise with in-house backgrounds to develop multijurisdictional IP protection strategies across antibiotics, antivirals, immunomodulators and vaccines, as well as diagnostic methods and technologies.  

The anti-infectives team specialises in patent and trade mark protection, with targeted and industry-validated advice on drafting and prosecuting, including second medical use type claims and cross jurisdictional drafting of patent applications. Furthermore, the attorneys are highly accomplished across oppositions and appeals in biologics, small molecule drugs and diagnostic devices, freedom-to-operate analysis, in-and-out licensing and supplementary protection certificates (SPCs).